Moderate-to-severe allergic rhinitis / rhino-conjunctivitis due to house dust mites (HDM) for at least one year according to the "Allergic Rhinitis and its Impact on Asthma" (ARIA research hub

Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy

This study is testing a new injection treatment for house dust mite allergy. It aims to see if different doses of the treatment can reduce hay fever-like symptoms like sneezing and runny nose, and if it's safe to use, compared to a dummy injection.